<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. ________)*
SpectRx, Inc.
- ------------------------------------------------------------------------------
(Name of Issuer)
Common stock par value $.001 per share
- ------------------------------------------------------------------------------
(Title of Class of Securities)
847 635 109
-------------------------------
(CUSIP Number)
Jose M. de Lasa, 100 Abbott Park Road
Abbott Park, Illinois 60064-3500; Phone (847) 937-8905
- ------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
July 7, 1997
-------------------------------
(Date of Event which Requires
Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(3) or (4), check the following
box / /.
Check the following box if a fee is being paid with the statement / /. (A
fee is not required only if the reporting person: (1) has a previous
statement on file reporting beneficial ownership of more than five percent of
the class of securities described in Item 1; and (2) has filed no amendment
subsequent thereto reporting beneficial ownership of five percent or less of
such class.) (See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be filed
with the Commission. See Rule 13d-1(a) for other parties to whom copies are
to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section
of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
(Continued on following page(s))
Page 1 of 12 Pages
--
<PAGE>
------------------------- --------------------------
| CUSIP No. 847 635 109 | 13D | Page 2 of 12 Pages |
------------------------- --------------------------
----------------------------------------------------------------------------
| 1 | NAME OF REPORTING PERSON |
| | S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON |
| | |
| | Abbott Laboratories |
| | IRS Identification Number: 36-0698440 |
| | |
|----------------------------------------------------------------------------
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / / |
| | |
| | (b) /x/ |
|----------------------------------------------------------------------------
| 3 | SEC USE ONLY |
| | |
----------------------------------------------------------------------------
| 4 | SOURCE OF FUNDS* |
| | |
| | WC |
----------------------------------------------------------------------------
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO |
| | ITEMS 2(d) or 2(e) / / |
| | |
----------------------------------------------------------------------------
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION |
| | |
| | Illinois |
----------------------------------------------------------------------------
| | 7 | SOLE VOTING POWER |
| NUMBER OF | | |
| | | 500,143 |
| SHARES |---------------------------------------------------------
| | 8 | SHARED VOTING POWER |
| BENEFICIALLY | | |
| |---------------------------------------------------------
| OWNED BY | 9 | SOLE DISPOSITIVE POWER |
| | | |
| EACH REPORTING | | 500,143 |
| ---------------------------------------------------------
| PERSON | 10| SHARED DISPOSITIVE POWER |
| | | |
| WITH | | |
----------------------------------------------------------------------------
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
| | |
| | 500,143 |
----------------------------------------------------------------------------
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN |
| | SHARES* / / |
|
----------------------------------------------------------------------------
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) |
| | |
| | 6.61% |
----------------------------------------------------------------------------
| 14 | TYPE OF REPORTING PERSON* |
| | |
| | CO |
----------------------------------------------------------------------------
* SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
ITEM 1. SECURITY AND ISSUER
This statement relates to shares of the common stock, par value
$.001 per share (the "Common Stock"), of SpectRx, Inc., a Delaware
corporation (the "Issuer"), whose principal executive offices are located at
6025A, Unity Drive, Norcross, Georgia, 30071.
ITEM 2. IDENTITY AND BACKGROUND
(a) - (c), and (f) The person filing this statement is Abbott
Laboratories ("Abbott"), an Illinois corporation. Abbott's principal
business is the discovery, development, manufacture, and sale of a broad and
diversified line of health care products and services. Abbott's principal
office is located at 100 Abbott Park Road, Abbott Park, Illinois 60064-3500.
The names, citizenship, business addresses, present principal
occupation or employment and the name, and the principal business and address
of any corporation or other organization in which such employment is
conducted of the directors and executive officers of Abbott are as set forth
in Exhibit 1 hereto and incorporated herein by this reference.
(d) and (e) Neither Abbott, nor to the best of its knowledge, any
person listed on Exhibit 1 has during the last five years (i) been convicted
in a criminal proceeding (excluding traffic violations or similar
misdemeanors) or (ii) been a party to a civil proceeding of a judicial or
administrative body of competent jurisdiction and as a result of such
proceeding was or is subject to a judgment, decree or final order enjoining
future violations of, or prohibiting or mandating activities subject to,
federal or state securities laws or finding any violation with respect to
such laws.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
On July 7, 1997, Abbott purchased 143,000 shares of Common Stock and
paid $1,001,000 for these 143,000 shares. These funds came from Abbott's
general assets.
3
<PAGE>
ITEM 4. PURPOSE OF THE ACQUISITION
Abbott acquired the shares of Common Stock as an investment.
(a) - (j) At present, Abbott does not have any plans or proposals
which would relate to or result in transactions of the kind described in
paragraphs (a) through (j) of Item 4 of Schedule 13D of the Securities and
Exchange Commission. Abbott does, however, reserve the right to adopt such
plans or proposals subject to compliance with applicable regulatory
requirements.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
(a) Abbott is the beneficial owner of 500,143 shares of Common
Stock. This represents approximately six and 61/100 percent (6.61%) of the
outstanding shares of the Common Stock. The calculation of the foregoing
percentage is based on the number of shares of Common Stock shown as being
outstanding in the Issuer's prospectus dated July 1, 1997.
(b) Abbott has sole power to vote or to direct the vote and the
sole power to dispose or to direct the disposition of the Shares.
(c) Except as described herein, there have been no transactions by
Abbott or the persons whose names are listed on Exhibit 1 in securities of
the Issuer during the past sixty days.
(d) No one other than Abbott is known to have the right to receive
or the power to direct the receipt of dividends from, or the proceeds from a
sale of the Shares.
(e) Not applicable.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT
TO SECURITIES OF THE ISSUER
None
4
<PAGE>
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS
Exhibit 1 - Information Concerning Executive Officers and
Directors of Abbott Laboratories.
*******************************
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Abbott Laboratories
DATED: July 14, 1997 By: /s/ Gary P. Coughlan
----------------------------------------
Gary P. Coughlan, Senior Vice President,
Finance and Chief Financial Officer
5
<PAGE>
EXHIBIT INDEX
EXHIBIT NUMBER DESCRIPTION SEQUENTIAL PAGE
NUMBER
1 Information Concerning Executive
Officers and Directors of
Abbott Laboratories.
6
<PAGE>
Exhibit 1
Information Concerning Executive Officers and
Directors of Abbott Laboratories
-----------------------------------
The current corporate officers and directors of Abbott Laboratories
are listed below. The address of Abbott Laboratories is: Abbott
Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064-3500.
Abbott Laboratories does not consider all of its corporate officers to be
executive officers as defined by the Securities Exchange Act of 1934 or
Releases thereunder. Unless otherwise indicated, all positions set forth
below opposite an individual's name refer to positions within Abbott
Laboratories, and the business address listed for each individual not
principally employed by Abbott Laboratories is also the address of the
corporation or other organization which principally employs that
individual.
POSITION/PRESENT PRINCIPAL
OCCUPATION OR EMPLOYMENT
NAME AND BUSINESS ADDRESS CITIZENSHIP
CORPORATE OFFICERS
Duane L. Burnham(1) Chairman of the Board and U. S. A.
Chief Executive Officer
Thomas R. Hodgson(1) President and Chief Operating U. S. A.
Officer
Joy A. Amundson(1) Senior Vice President, U. S. A.
Chemical and Agricultural Products
Paul N. Clark(1) Senior Vice President, U. S. A.
Pharmaceutical Operations
Gary P. Coughlan(1) Senior Vice President, Finance U. S. A.
and Chief Financial Officer
Jose M. de Lasa(1) Senior Vice President, Secretary U. S. A.
and General Counsel
John G. Kringel(1) Senior Vice President, Hospital U. S. A.
Products
Thomas M. McNally(1) Senior Vice President, Ross Products U. S. A.
Robert L. Parkinson, Senior Vice President, International U. S. A.
Jr.(1) Operations
Ellen M. Walvoord(1) Senior Vice President, Human Resources U. S. A.
Miles D. White(1) Senior Vice President, Diagnostic U. S. A.
Operations
7
<PAGE>
Exhibit 1
Information Concerning Executive Officers and
Directors of Abbott Laboratories
-----------------------------------
POSITION/PRESENT PRINCIPAL
OCCUPATION OR EMPLOYMENT
NAME AND BUSINESS ADDRESS CITIZENSHIP
CORPORATE OFFICERS -
Continued
Catherine V. Babington(1) Vice President, Investor Relations U. S. A.
and Public Affairs
Patrick J. Balthrop Vice President, Diagnostic U. S. A.
Operations, U.S. and Canada
Mark E. Barmak Vice President, Litigation and U. S. A.
Government Affairs
Christopher B. Begley Vice President, MediSense U. S. A.
Thomas D. Brown Vice President, Diagnostic U. S. A.
Commercial Operations
Gary R. Byers(1) Vice President, Internal Audit U. S. A.
William G. Dempsey Vice President, Hospital Products U. S. A.
Business Sector
Kenneth W. Farmer(1) Vice President, Management U. S. A.
Information Services and
Administration
Thomas C. Freyman(1) Vice President and Treasurer U. S. A.
David B. Goffredo Vice President, Pharmaceutical U. S. A.
Products Marketing and Sales
Rick A. Gonzalez(1) Vice President, HealthSystems U. S. A.
8
<PAGE>
Exhibit 1
Information Concerning Executive Officers and
Directors of Abbott Laboratories
-----------------------------------
POSITION/PRESENT PRINCIPAL
OCCUPATION OR EMPLOYMENT
NAME AND BUSINESS ADDRESS CITIZENSHIP
CORPORATE OFFICERS -
Continued
Guillermo A. Herrera Vice President, Latin America Columbia
Operations
Arthur J. Higgins Vice President, Pacific, Asia, United
and Africa Operations Kingdom
Jay B. Johnston Vice President, Diagnostic Assays U. S. A.
and Operations
James J. Koziarz, Ph.D. Vice President, Diagnostic U. S. A.
Products Research and Development
John F. Lussen(1) Vice President, Taxes U. S. A.
Edward L. Michael Vice President, Diagnostic U. S. A.
Operations, Europe, Africa, and
Middle East
Theodore A. Olson(1) Vice President and Controller U. S. A.
Andre G. Pernet, Ph.D. Vice President, Pharmaceutical U. S. A.
Products Research and Development
Carl A. Spalding Vice President, Ross Pediatric U. S. A.
Products
William H. Stadtlander Vice President, Ross Medical U. S. A.
Nutritional Products
Marcia A. Thomas(1) Vice President, Corporate Quality U. S. A.
Assurance and Regulatory Affairs
H. Thomas Watkins Vice President, Diagnostic U. S. A.
Operations, Asia and Pacific
Steven J. Weger(1) Vice President, Corporate Planning U. S. A.
and Development
Josef Wendler Vice President, European Operations Germany
Lance B. Wyatt(1) Vice President, Corporate U. S. A.
Engineering
9
<PAGE>
Exhibit 1
Information Concerning Executive Officers and
Directors of Abbott Laboratories
-----------------------------------
POSITION/PRESENT PRINCIPAL
OCCUPATION OR EMPLOYMENT
NAME AND BUSINESS ADDRESS CITIZENSHIP
DIRECTORS
K. Frank Austen, M.D. Professor of Medicine, Harvard U. S. A.
Medical School
The Seeley G. Mudd Building,
Room 604
250 Longwood Avenue
Boston, Massachusetts 02115
Duane L. Burnham Officer of Abbott U. S. A.
H. Laurance Fuller Chairman, President, and Chief U. S. A.
Executive Officer
Amoco Corporation
200 East Randolph Drive
Mail Code 3000
Chicago, Illinois 60601
(integrated petroleum and
chemicals company)
Thomas R. Hodgson Officer of Abbott U. S. A.
David A. Jones Chairman and Chief Executive Officer U. S. A.
Humana Inc.
500 W. Main St.
Humana Building
Louisville, Kentucky 40201
(Health Plan Business)
The Rt. Hon. the Lord British Member of Parliament United Kingdom
Owen CH 20 Queen Anne's Gate
Westminster, London
SW1H 9AA, England
10
<PAGE>
Exhibit 1
Information Concerning Executive Officers and
Directors of Abbott Laboratories
-----------------------------------
POSITION/PRESENT PRINCIPAL
OCCUPATION OR EMPLOYMENT
NAME AND BUSINESS ADDRESS CITIZENSHIP
DIRECTORS - CONTINUED
Boone Powell, Jr. President and Chief Executive U. S. A.
Officer
Baylor Health Care System and
Baylor University Medical
Center,
Vice President, Baylor University
3500 Gaston Avenue
Dallas, Texas 75246
Addison Barry Rand Executive Vice President U. S. A.
Xerox Corporation
800 Long Ridge Road
Stamford, Connecticut
06904-1600
(document processing, insurance
and financial services company)
Dr. W. Ann Reynolds Chancellor U. S. A.
The City University of New York
535 E. 80th Street
New York, New York 10021
William D. Smithburg Chairman, President and Chief U. S. A.
Executive Officer
The Quaker Oats Company
321 N. Clark Street
Chicago, Illinois 60610
(worldwide food manufacturer
and marketer of beverages and
grain-based products)
John R. Walter President and Chief Operating U. S. A.
Officer
AT&T Corporation
295 North Maple Avenue
Room 4353L1
Basking Ridge, New Jersey 07920
(telecommunications company)
11
<PAGE>
Exhibit 1
Information Concerning Executive Officers and
Directors of Abbott Laboratories
-----------------------------------
POSITION/PRESENT PRINCIPAL
OCCUPATION OR EMPLOYMENT
NAME AND BUSINESS ADDRESS CITIZENSHIP
DIRECTORS - CONTINUED
William L. Weiss Chairman Emeritus, Ameritech U. S. A.
Corporation
One First National Plaza
Suite 2530C
Chicago, Illinois 60603-2006
(telecommunications company)
1 Pursuant to Item 401(b) of Regulation S-K Abbott has identified these
persons as "executive officers" within the meaning of Item 401(b).
12